Piper Sandler raised the firm’s price target on Crispr Therapeutics (CRSP) to $110 from $105 and keeps an Overweight rating on the shares. The firm notes the company issued $600M note due in March 2031 convertible at $76.56 per share with an effective coupon of 1.73%. Piper estimates Crispr now holds pro forma cash of $2.56B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics Completes $600 Million Convertible Notes Offering
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today
- CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
- Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million